Diabetic Gastroparesis Management

Pathophysiology and Prevalence

Diabetic gastroparesis, defined as delayed gastric emptying without mechanical obstruction, is estimated to affect 20-40% of patients with diabetes mellitus, particularly those with long-standing type 1 diabetes with other complications 1
The etiology is multifactorial, including diabetic vagal neuropathy, hyperglycemia-induced antral hypomotility, gastric dysrhythmias, and interstitial cells of Cajal network disturbances 1

Common symptoms of diabetic gastroparesis include nausea, vomiting, postprandial fullness, early satiety, bloating, and upper abdominal pain 1
Diagnosis is based on the presence of appropriate symptoms, documentation of delayed gastric emptying, and exclusion of mechanical obstruction 1
Gastric emptying scintigraphy is considered the gold standard diagnostic test, with gastric retention of more than 60% at 2 hours having 100% sensitivity for diagnosis 1

The American Diabetes Association recommends implementing low-fat, low-fiber meals with smaller, more frequent feedings (5-6 meals per day) 2
Focus on foods with small particle size to improve key symptoms 3, 2
Maintain glucose levels below 180 mg/dL to minimize symptoms 3
Near-normal glycemic control implemented early in diabetes can delay or prevent development of diabetic neuropathy and associated digestive complications 4
Metoclopramide (10 mg three times daily before meals) is the only FDA-approved medication for gastroparesis and should be the first-line pharmacologic treatment 3
Initial treatment with metoclopramide should be for at least 4 weeks to determine efficacy 2
Be aware of the black box warning for tardive dyskinesia with metoclopramide use; FDA recommends against use beyond 12 weeks 4

Jejunostomy tube feeding should be considered for patients unable to maintain adequate oral intake 2
Decompressing gastrostomy may be necessary in some cases of severe gastroparesis 2
Botulinum toxin injection into the pyloric sphincter may provide modest temporary symptom improvement in selected patients 2
Gastric per-oral endoscopic myotomy (G-POEM) may be considered in severe cases 2

Continuing metoclopramide beyond 12 weeks without careful reassessment due to risk of tardive dyskinesia 2
Failing to recognize medication-induced gastroparesis (e.g., from opioids, GLP-1 agonists) 3, 2
Neglecting to assess for other diabetic complications such as cardiovascular autonomic neuropathy, which often coexists with gastroparesis 5